NCT06997094 - Decitabine in Combination With Standard of Care Therapy for the Treatment of Surgically Resectable HPV-Negative Head and Neck Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 8, 2025

Primary Completion Date

July 8, 2027

Study Completion Date

July 8, 2027

Conditions

Human Papillomavirus-Negative Neck Squamous Cell CarcinomaResectable Head and Neck Squamous Cell CarcinomaResectable Human Papillomavirus-Independent Head and Neck Mucosal Squamous Cell CarcinomaHPV-Negative Squamous Cell CarcinomaResectable Head and Neck Squamous-cell Carcinoma

Interventions

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

DRUG

Chemotherapy

Given concurrent chemotherapy

DRUG

Decitabine

Given IV

RADIATION

External Beam Radiation Therapy

Undergo EBRT

OTHER

Questionnaire Administration

Ancillary studies

PROCEDURE

Surgical Procedure

Undergo standard of care surgery

Trial Locations (1)

32224-9980

Mayo Clinic in Florida, Jacksonville